160 related articles for article (PubMed ID: 34195582)
1. Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data.
Swart N; Maroni R; Muldrew B; Sasieni P; Fitzgerald RC; Morris S;
EClinicalMedicine; 2021 Jul; 37():100969. PubMed ID: 34195582
[TBL] [Abstract][Full Text] [Related]
2. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
3. Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
Offman J; Muldrew B; O'Donovan M; Debiram-Beecham I; Pesola F; Kaimi I; Smith SG; Wilson A; Khan Z; Lao-Sirieix P; Aigret B; Walter FM; Rubin G; Morris S; Jackson C; Sasieni P; Fitzgerald RC;
BMC Cancer; 2018 Aug; 18(1):784. PubMed ID: 30075763
[TBL] [Abstract][Full Text] [Related]
4. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
7. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning.
Berman AG; Tan WK; O'Donovan M; Markowetz F; Fitzgerald RC
EBioMedicine; 2022 Aug; 82():104160. PubMed ID: 35843173
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.
Ross-Innes CS; Debiram-Beecham I; O'Donovan M; Walker E; Varghese S; Lao-Sirieix P; Lovat L; Griffin M; Ragunath K; Haidry R; Sami SS; Kaye P; Novelli M; Disep B; Ostler R; Aigret B; North BV; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Sasieni PD; Fitzgerald RC;
PLoS Med; 2015 Jan; 12(1):e1001780. PubMed ID: 25634542
[TBL] [Abstract][Full Text] [Related]
11. Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial.
Ghimire B; Landy R; Maroni R; Smith SG; Debiram-Beecham I; Sasieni PD; Fitzgerald RC; Rubin G; Walter FM; Waller J; ; Offman J
BMC Gastroenterol; 2023 Jan; 23(1):7. PubMed ID: 36627580
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.
Maroni R; Barnes J; Offman J; Scheibl F; Smith SG; Debiram-Beecham I; Waller J; Sasieni P; Fitzgerald RC; Rubin G; ; Walter FM
BMJ Open; 2022 Apr; 12(4):e054258. PubMed ID: 35393308
[TBL] [Abstract][Full Text] [Related]
13. Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy.
Eluri S; Paterson A; Lauren BN; O'Donovan M; Bhandari P; di Pietro M; Lee M; Haidry R; Lovat L; Ragunath K; Hur C; Fitzgerald RC; Shaheen NJ
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e51-e63. PubMed ID: 33581357
[TBL] [Abstract][Full Text] [Related]
14. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
[TBL] [Abstract][Full Text] [Related]
17. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
[TBL] [Abstract][Full Text] [Related]
18. Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device-The Cytosponge
Paterson AL; Gehrung M; Fitzgerald RC; O'Donovan M
Diagn Cytopathol; 2020 Mar; 48(3):253-264. PubMed ID: 31814330
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
